0001725430 2025-07-01 2026-06-30 0001725430 2025-12-31 0001725430 2026-08-18 0001725430 2023-10-02 2024-07-01 2025-06-30 iso4217:USD shares true FY 0001725430 No No Yes Yes 10-K/A true 2026-06-30 --06-30 2026 false 001-39825 Intelligent Bio Solutions Inc. DE 82-1512711 135 West 41st Street 5th Floor New York NY 10036 (646) 790-5756 Common Stock, par value $0.01 per share INBS NASDAQ Non-accelerated Filer true false false false false 11712017 3027470 None 1195 UHY LLP Melville, NY Intelligent Bio Solutions Inc. (the “Company,” “we,” “us” or “our”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment No. 1”) to amend its Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the “Original 10-K”), originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 19, 2026, solely for the purpose of amending and restating in their entirety Item 11, Item 13, and Item 15 of the Original 10-K, as described below. Specifically, this Amendment No. 1 is being filed to (i) revise Item 11 to remove duplicate disclosure regarding Outstanding Equity Awards at Fiscal Year End that appeared immediately following the footnotes to the Summary Compensation Table; (ii) revise Item 13 to add disclosure regarding capital raising transactions in which a beneficial owner of more than 5% of our outstanding common stock participated, clarify the process used to approve related party transactions, and to make related and other clarifying revisions; (iii) revise the Exhibit Index in Item 15 to delete a duplicate entry for a Certificate of Amendment to the Company’s Certificate of Incorporation listed as Exhibit 3.1 and to replace that entry with the Company’s Amended and Restated Certificate of Incorporation; and (iv) revise the Exhibit Index in Item 15 to remove two duplicate entries previously listed as Exhibits 10.39 and 10.40 and to make conforming updates to the exhibit numbering and references. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment No. 1 also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV is also amended to include the currently dated certifications of our principal executive officer and principal financial officer as exhibits. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 1, new certifications of our principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with this Amendment No. 1. Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the date of the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original 10-K. Defined terms used, but not defined, herein have the meanings ascribed to them in the Original 10-K. We adopted the Intelligent Bio Solutions, Inc. Dodd-Frank Restatement Recoupment Policy effective as of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFJlY292ZXJ5IG9mIEVycm9uZW91c2x5IEF3YXJkZWQgQ29tcGVuc2F0aW9uAA__" id="xdx_902_eecd--RestatementDeterminationDate_iB_dd_c20240701__20250630__ecd--RestatementDateAxis__2023-10-02_zPnn7JOLXQCf">October 2, 2023. In the event that we are required to prepare a financial restatement, the Compensation Committee will recoup all erroneously awarded incentive-based compensation calculated on a pre-tax basis received after October 2, 2023, by a person (i) after beginning service as an executive officer, (ii) who served as an executive officer at any time during the performance period for that incentive-based compensation, and (iii) during the three completed fiscal years immediately preceding the date that the Company is required to prepare a restatement, and any transition period (that results from a change in the Company’s fiscal year) of less than nine months within or immediately following those three completed fiscal years. “Clawback” or recoupment policy in our executive compensation program contributes to creating and maintaining a culture that emphasizes integrity and accountability and reinforces the performance-based principles underlying our executive compensation program. 2023-10-02 We do not grant stock options, stock appreciation rights, or option-like instruments (collectively, “Option-Like Awards”) in anticipation of the release of material nonpublic information and we do not time the public release of such information based on the grant dates of Option-Like Awards. During the last completed fiscal year, we have not awarded Option-Like Awards to any named executive officer during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. We do not grant stock options, stock appreciation rights, or option-like instruments (collectively, “Option-Like Awards”) in anticipation of the release of material nonpublic information and we do not time the public release of such information based on the grant dates of Option-Like Awards. false During the last completed fiscal year, we have not awarded Option-Like Awards to any named executive officer during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. false